ArticleJournal of health, population, and nutrition2025
Economic burden and quality of life caused by non-hodgkin lymphoma cancer in Iran.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-Hodgkin's lymphoma (NHL) poses significant clinical and economic challenges in Iran, where rising cancer rates strain healthcare systems and compromise patient quality of life. This study assesses the direct and indirect costs associated with NHL and their impact on patient well-being.
methodsA cross-sectional, descriptive-analytical study was conducted over a six-month period at Omid Hospital in Mashhad, Iran. Data were collected through face-to-face interviews with 83 NHL patients using validated questionnaires adapted to capture detailed information on direct medical and non-medical expenses, as well as productivity losses. Quality of life (QOL) was assessed via the EQ-5D and EORTC QLQ-C30 instruments. Statistical analyses, including regression models performed in STATA, were employed to examine associations between disease stage, costs, and QOL.
resultsDirect treatment costs by stage were $1,078.11 ± $631.45 (stage 1), $583.40 ± $289.73 (stage 2), $810.42 ± $324.46 (stage 3), and $662.59 ± $361.70 (stage 4). Indirect costs were $56.72 ± $7.36 (stage 1), $82.80 ± $21.39 (stage 2), $105.15 ± $24.02 (stage 3), and $116.32 ± $34.92 (stage 4), totaling $1,334.63 ± $711.56 (stage 1), $1,161.43 ± $494.97 (stage 2), $1,297.07 ± $337.16 (stage 3), and $1,119.32 ± $457.27 (stage 4). EQ-5D scores fell from 0.63 ± 0.23 (stage 1) to 0.43 ± 0.29 (stage 4) at baseline, reflecting similar trends after six months. These results suggest that overall QOL, as measured by QOL, tends to decrease as the disease progresses from stage 1 to stage 4. However, there may be some variations in QOL changes between different stages.
conclusionThese findings underscore the substantial economic burden of NHL and its adverse impact on patient quality of life in Iran. Early diagnosis, improved access to specialized cancer centers, and increased financial support are crucial for enhancing health outcomes for NHL patients. Implementing these studies can improve patient access to care and boost overall health outcomes in society.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.